Common Variants on FGD5 Increase Hazard of Mortality or Rehospitalization in Patients With Heart Failure From the ASCEND-HF Trial.

MLA

Hongsheng Gui, et al. “Common Variants on FGD5 Increase Hazard of Mortality or Rehospitalization in Patients With Heart Failure From the ASCEND-HF Trial.” Circulation: Heart Failure, vol. 16, no. 9, Sept. 2023, pp. 776–86. EBSCOhost, https://doi.org/10.1161/CIRCHEARTFAILURE.122.010438.

APA

Hongsheng Gui, Tang, W. H. W., Francke, S., Jia Li, Ruicong She, Bazeley, P., Pereira, N. L., Adams, K., Luzum, J. A., Connolly, T. M., Hernandez, A. F., McNaughton, C. D., Williams, L. K., & Lanfear, D. E. (2023). Common Variants on FGD5 Increase Hazard of Mortality or Rehospitalization in Patients With Heart Failure From the ASCEND-HF Trial. Circulation: Heart Failure, 16(9), 776–786. https://doi.org/10.1161/CIRCHEARTFAILURE.122.010438

Chicago

Hongsheng Gui, W. H. Wilson Tang, Stephan Francke, Jia Li, Ruicong She, Peter Bazeley, Naveen L. Pereira, et al. 2023. “Common Variants on FGD5 Increase Hazard of Mortality or Rehospitalization in Patients With Heart Failure From the ASCEND-HF Trial.” Circulation: Heart Failure 16 (9): 776–86. doi:10.1161/CIRCHEARTFAILURE.122.010438.